Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts

Analysts' ratings for Ultragenyx Pharmaceutical RARE over the last quarter vary from bullish to bearish, as provided by 9 analysts.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $94.33, a high estimate of $114.00, and a low estimate of $48.00. This current average reflects an increase of 22.19% from the previous average price target of $77.20.

Deciphering Analyst Ratings: An In-Depth Analysis

In examining recent analyst actions, we gain insights into how financial experts perceive Ultragenyx Pharmaceutical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ultragenyx Pharmaceutical. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Ultragenyx Pharmaceutical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Capture valuable insights into Ultragenyx Pharmaceutical's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Ultragenyx Pharmaceutical analyst ratings.

Unveiling the Story Behind Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Breaking Down Ultragenyx Pharmaceutical's Financial Performance

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Over the 3 months period, Ultragenyx Pharmaceutical showcased positive performance, achieving a revenue growth rate of 23.27% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -96.7%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -80.22%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -9.03%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Ultragenyx Pharmaceutical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.

The Basics of Analyst Ratings

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.